Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • Evoke Pharma's Accumulated Expenses rose 2515.55% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 2515.55%. This contributed to the annual value of $2.1 million for FY2024, which is 3109.67% up from last year.
  • Per Evoke Pharma's latest filing, its Accumulated Expenses stood at $2.5 million for Q3 2025, which was up 2515.55% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Accumulated Expenses ranged from a high of $2.5 million in Q3 2025 and a low of $400251.0 during Q1 2023
  • In the last 5 years, Evoke Pharma's Accumulated Expenses had a median value of $810790.0 in 2021 and averaged $1.2 million.
  • As far as peak fluctuations go, Evoke Pharma's Accumulated Expenses tumbled by 4889.78% in 2021, and later surged by 33396.59% in 2024.
  • Evoke Pharma's Accumulated Expenses (Quarter) stood at $519317.0 in 2021, then grew by 13.83% to $591158.0 in 2022, then soared by 172.74% to $1.6 million in 2023, then surged by 31.1% to $2.1 million in 2024, then increased by 17.69% to $2.5 million in 2025.
  • Its Accumulated Expenses stands at $2.5 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.2 million for Q1 2025.